Physician profile
Rita M Schultz
NPI 1124116926
$5,399.03
in general payments reported to CMS, 2019-2025
33 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $546 · 2021: $655 · 2022: $393 · 2023: $756 · 2024: $975 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,856 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,856.44 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $862.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $724.25 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $691.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $678.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $555.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $391.57 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $190.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.82 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $151.39 | 2019-2023 | Trintellix |
| Genentech USA, INC. | $114.72 | 2019-2022 | |
| Allergan, INC. | $91.43 | 2020 | |
| Cmp Pharma, INC. | $83.78 | 2022 | |
| Phathom Pharmaceuticals, INC. | $73.61 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $64.25 | 2019-2021 | |
| Abbott Laboratories | $62.42 | 2019-2023 | Proclaim, Octrode |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.27 | 2021-2022 | |
| Astellas Pharma US INC | $46.69 | 2019-2023 | Myrbetriq |
| Gilead Sciences, INC. | $44.41 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.51 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $38.67 | 2024-2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $35.57 | 2019 | |
| Axsome Therapeutics, INC. | $35.05 | 2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $30.84 | 2021 | |
| Sanofi Pasteur INC. | $27.58 | 2019 | |
| Exact Sciences Corporation | $27.44 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $25.70 | 2019-2021 | |
| Dexcom, INC. | $24.30 | 2024 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $24.04 | 2023 | Daybue |
| Exeltis, USA INC. | $17.34 | 2024 | Slynd |
| Ironshore Pharmaceuticals INC. | $16.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.56 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.